What is the difference between adjuvant and neoadjuvant treatment for Ovarian Cancer

Adjuvant vs. Neoadjuvant Treatment for Ovarian Cancer

Great question—understanding the timing and purpose of these treatments is important for your care planning.

The Key Difference: Timing

Neoadjuvant treatment happens before surgery, while adjuvant treatment happens after surgery. This timing difference affects how doctors approach your overall treatment strategy.

---

NEOADJUVANT TREATMENT (Before Surgery)

What It Is:

Chemotherapy or other systemic therapy given first, before your surgical procedure.

Why Doctors Use It:

• Shrink the tumor to make surgery safer and more effective
• Reduce tumor burden (the total amount of cancer) before the surgeon operates
• Assess how your tumor responds to specific drugs—this helps doctors understand which treatments are working best for YOUR cancer
• Improve surgical outcomes by making the cancer easier to remove completely

Clinical Benefit:

According to the medical literature on precision medicine approaches, understanding how your specific tumor responds to treatment before surgery can be valuable. As discussed in the CancerPatientLab webinars on personalized treatment, testing tumor sensitivity to drugs helps oncologists tailor therapy to your individual cancer's characteristics.

---

ADJUVANT TREATMENT (After Surgery)

What It Is:

Chemotherapy or other systemic therapy given after your surgery is complete.

Why Doctors Use It:

• Eliminate remaining cancer cells that may have spread beyond what the surgeon could see or remove
• Reduce recurrence risk (the chance cancer comes back)
• Improve long-term survival outcomes
• Standard approach for most ovarian cancer patients, especially those with advanced disease

Clinical Benefit:

Adjuvant therapy is considered standard of care for most ovarian cancer patients. As noted in the medical literature, adjuvant therapy for patients with nodal disease (cancer in lymph nodes) can sometimes show a survival benefit of about 20%—meaning one out of five patients may have long-term benefit from this treatment.

---

Which One Will You Receive?

Your oncologist will recommend neoadjuvant, adjuvant, or both based on:

✓ Stage of your cancer (how advanced it is)
✓ Whether surgery is immediately possible (sometimes tumors are too large or spread too widely)
✓ Your overall health and ability to tolerate treatment
✓ Specific characteristics of your tumor (biomarkers, genetic mutations like BRCA)
✓ Goals of treatment (cure vs. disease control)

---

Important Questions to Ask Your Oncologist

1. Am I a candidate for neoadjuvant treatment, and if so, why?
2. What chemotherapy drugs are you recommending, and how do you know they'll work for my specific cancer?
3. How will we measure whether the treatment is working? (imaging, tumor markers, etc.)
4. What happens after surgery—will I need adjuvant treatment as well?
5. Are there any tumor sensitivity tests available to guide which drugs to use?
6. What are the expected side effects, and how will we manage them?

---

The Emerging Precision Medicine Approach

An important development in cancer care is testing your tumor's response to specific drugs before committing to treatment. As discussed in CancerPatientLab webinars on personalized treatment recommendations, some oncologists now use tumor sensitivity testing to understand which drugs are most likely to work for YOUR cancer specifically—rather than using a one-size-fits-all approach.

This is particularly relevant for ovarian cancer patients, as understanding your tumor's individual characteristics can help guide both neoadjuvant and adjuvant treatment decisions.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.